FDA.reportPublic FDA data

0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]

RxCUI
2696267
RxNorm name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Display name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Full name
0.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:20

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761298Pavbluaflibercept-ayyh351(k) BiosimilarRx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PAVBLUAFLIBERCEPT-AYYHAmgen, Incc61062f3-80ec-4a20-8c28-46e468592a062026-05-10Warnings, Adverse reactionsExact identifier
rxcui: 2696267

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
c61062f3-80ec-4a20-8c28-46e468592a060.05 ML aflibercept-ayyh 40 MG/ML Prefilled Syringe [Pavblu]SBD9These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260510
c61062f3-80ec-4a20-8c28-46e468592a06PAVBLU 2 MG in 0.05 ML Prefilled SyringePSN9These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260510
c61062f3-80ec-4a20-8c28-46e468592a06Pavblu 2 MG per 0.05 ML Prefilled SyringeSY9These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260510
c61062f3-80ec-4a20-8c28-46e468592a060.05 ML Pavblu 40 MG/ML Prefilled SyringeSY9These highlights do not include all the information needed to use PAVBLU safely and effectively. See full prescribing information for PAVBLU. PAVBLU ® (aflibercept-ayyh) injection, for intravitreal use Initial U.S. Approval: 2024 PAVBLU (aflibercept-ayyh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee20260510